InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Explore the detailed record of transactions filed by Kewalramani Reshma, Chairman & CEO. Director active across 2 companies, notably Vertex Pharmaceuticals INC / MA. Aggregated, 9 disclosures have been recorded. Total volume traded: €5.2m. The latest transaction was disclosed on 24 June 2022 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations9 total
€3m11,689 shares@ €276.89810.0029% mcap35.9% of flow
Common Stock
SEC:0000899243-22-024385:0·
070,921 shares0
Class A Common Stock
SEC:0000899243-22-022285:0·
€1m7,246 shares@ €201.54450.0013% mcap16.2% of flow
Common Stock
SEC:0000899243-22-008116:0·
€2m8,584 shares@ €204.39950.0016% mcap19.5% of flow
Common Stock
SEC:0000899243-22-007208:0·
€630,9053,031 shares@ €208.15090.0006% mcap7.0% of flow
Common Stock
SEC:0001209191-22-009236:0·
09,800 shares0
Common Stock
SEC:0001209191-22-006775·
09,800 shares0
Common Stock
SEC:0001209191-22-006775:0·
€962,1135,757 shares@ €167.1206100.0% of flow
Common Stock
SEC:0001209191-21-052881·
Ideal exit: 16 May 2022 (T+270)
€962,1135,757 shares@ €167.12060.0009% mcap10.7% of flow
Common Stock
SEC:0001209191-21-052881:0·
Ideal exit: 16 May 2022 (T+270)
9 of 9 declarations
About Kewalramani Reshma
Reshma Kewalramani is the CEO & President and Board Member at Vertex Pharmaceuticals Inc. and Ginkgo Bioworks Holdings, Inc. She oversees the operations of both companies and is responsible for the overall strategy. Her leadership is essential for growth and innovation in the biopharmaceutical sector.
